Why Is Replimune Stock Trading Lower On Monday?
1. Replimune's skin cancer treatment rejected by the FDA, causing a stock plunge. 2. Stock fell nearly 43% over one month, with very high trading volume. 3. FDA's internal turmoil affected the review process and approval decision. 4. A lawsuit claims Replimune misled investors on drug prospects. 5. Stock currently trading around $5.48, down 27.9% from previous close.